書籍詳細

PART 1 わが国における糖尿病の現状と展望をみる

P.9 掲載の参考文献

• 1) 厚生労働省:健康局総務課生活習慣病対策室. 平成14年度, 糖尿病実態調査. 厚生労働省, 2003

• 2) 厚生省保健医療局生活習慣病対策室. 平成9年度, 糖尿病実態調査. 厚生省, 1999

• 3) 厚生統計協会:国民衛生の動向 52:414-417, 2005

• 4) 日本透析医学会統計調査委員会・同小委員会:わが国の慢性透析療法の現況. 日透析医学会誌 31:1-24, 2004

• 5) 赤澤好温:日本人糖尿病の疫学. 日本臨牀 55:541-551, 1997
  Medical*Online

P.13 掲載の参考文献

• 1) Porte D Jr:Banting lecture 1990. β-cells in type II diabetes mellitus. Diabetes 40:166-180, 1991

• 2) DeFronzo RA:Lilly lecture 1987. The triumvirate:β-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37:667-687, 1988

• 3) 葛谷健, 中川昌一, 佐藤譲ほか:糖尿病の分類と診断基準に関する委員会報告. 糖尿病 42:385-401, 1999

• 4) Fukushima M, Usami M, Ikeda M et al:Insulin secretion and insulin sensitivity at different stages of glucose tolerance:a cross-sectional study of Japanese type 2 diabetes. Metabolism 53:831-835, 2004
  pubmed

• 5) Fukushima M, Suzuki H, Seino Y:Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diab Res Clin Pract 66 (Suppl 1):S37-S43, 2004

• 6) Mitsui R, Fukushima M, Nishi Y et al:Factors responsible for deteriorating glucose tolerance in newly diagnosed type 2 diabetes in Japanese men. Metabolism 55:53-58, 2006
  pubmed

• 7) Suzuki H, Fukushima M, Usami M et al:Factors responsible for development from normal glucose tolerance to isolated postchallenge hyperglycemia. Diabetes Care 26:1211-1215, 2003
  pubmed

• 8) Knowler WC, Barrett-Connor E, Fowler SE et al:DPP research group, Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engt J Med 346:393-403, 2002

P.18 掲載の参考文献

• 1) 葛谷健, 中川昌一, 佐藤譲ほか:糖尿病の分類と診断基準に関する委員会報告. 糖尿病 42:385-404, 1999

• 2) Expert committee on the diagnosis and classifications of diabetes mellitus:Report of the expert committee on the diagnosis and classifications of diabetes mellitus. Diabetes Care 20:1183-1197, 1997
  pubmed

• 3) Tominaga M, Eguchi H, Manaka H et al:Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22:920-924, 1999

• 4) The DECODE study group:Glucose tolerance and mortality:comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354:617-621, 1999

• 5) 赤沼安夫, 伊藤千賀子, 岩本安彦ほか:糖尿病の指導区分に関する検討. 日本公衆衛生協会, 東京, 2001

P.22 掲載の参考文献

• 1) Tripathy D, Carlsson M, Almgren P et al:Insulin secretion and insulin sensitivity in relation to glucose tolerance. Lessons from the Botnia study. Diabetes 49:975-980, 2000
  pubmed

• 2) Petersen KF, Befroy D, Dufour S et al:Mitochondrial dysfunction in the elderly:possible role in insulin resistance. Science 300:1140-1142, 2003
  pubmed

• 3) Diabetes Prevention Program Research Group:Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002
  pubmed

P.28 掲載の参考文献

• 1) Kaplan NM, Rose BD:Treatment of hypertension in diabetes mellitus. UpTodate version 13. 1, metabolic syndrome の総説集

• 2) 日本糖尿病学会編:科学的根拠に基づく糖尿病診療ガイドライン. 南江堂, 東京, 2004

• 3) McFarlane SI, Castro J, Kirpichnikov D et al:Hypertension and diabetes. In:Joslin's Diabetes Mellitus 14th ed, eds. by Khan CR, Weir GC, King GL et al, Lippincott Williams & Wilkins, Philadelphia, 2004, pp.969-974

P.32 掲載の参考文献

• 1) Yamagishi S, Nakamura K, Jinnouchi Y et al:Therapeutic implications of blockers of advanced glycation end products (AGEs)-their receptor (RAGE) system. Int J Pharm 1:203-209, 2005

• 2) Beisswenger PJ, Howell SK, O'Dell RM et al:α-Dicarbonyls increase in the postprandial period and reflect the degree of hyperglycemia. Diabetes Care 24:726-732, 2001

• 3) Yamagishi S, Imaizumi T:Diabetic vascular complications:Pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 11:2279-2299, 2005
  pubmed

• 4) Ceriello A:Hyperglycaemia:the bridge between non-enzymatic glycation and oxidative stress in the pathogenesis of diabetic complications. Diabetes Nutr Metab 12:42-46, 1999

• 5) Yamagishi S, Nakamura K, Takeuchi M et al:Molecular mechanism for accelerated atherosclerosis in diabetes and its potential therapeutic intervention. Int J Clin Pharm Res 24:129-134, 2004

PART 2 実地医家による糖尿病治療の現状と課題点をみる

P.38 掲載の参考文献

• 1) Tamura Y, Tanaka Y, Sato F et al:Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 90:3191-3196, 2005
  pubmed

• 2) Sato F et al:presented at ADA, 2005

• 3) Knowler WC, Hamman RF, Edelstein SL et al:DPP Research Group:Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 54:1150-1156, 2005

• 4) Chiasson JL, Josse RG, Gomis R et al:Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance:the STOP-NIDDM trial. JAMA 290:486-494, 2003
  pubmed

• 5) Uchino H, Niwa M, Shimizu T et al:Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes:assessment using nateglinide, a new insulin secretagogue. Endocr J 47:639-641, 2000
  pubmed

• 6) Hirose T, Mizuno R, Yoshimoto T:The effects of nateglinide following oral glucose load in impaired glucose tolerance subjects:rapid insulin stimulation by nateglinide in IGT subjects. Endocr J 49:649-652, 2002
  pubmed

P.44 掲載の参考文献

• 1) Sone H, Katagiri A, Ishibashi S et al:JD Study Group:Effects of lifestyle modifications on patients with type 2 diabetes:the Japan Diabetes Complications Study (JDCS) study design, baseline analysis and three year-interim report. Horm Metab Res 34:509-515, 2002

• 2) Abate N, Chandalia M:The impact of ethnicity on type 2 diabetes. J Diabetes Complications 17:39-58, 2003
  pubmed

• 3) Valsamakis G, Chetty RK, Kumar S:The management of obesity in type 2 diabetes mellitus. Curr Med Res Opin 18 (Suppl 1):S75-S81, 2002

• 4) Nelson KM, Reiber G, Boyko EJ:NHANES III. Diet and exercise among adults with type 2 diabetes:findings from the third national health and nutrition examination survey (NHANES III). Diabetes Care 25:1722-1728, 2002
  pubmed

• 5) Sone H, Ito H, Ohashi Y et al:Japan Diabetes Complication Study Group:Obesity and type 2 diabetes in Japanese patients. Lancet 361:85, 2003

• 6) Saydah SH, Fradkin J, Cowie CC:Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 291:335-342, 2004
  pubmed

• 7) Sone H, Yoshimura Y, Ito H et al:Energy intake and obesity in Japanese patients with type 2 diabetes. Lancet 363:248-249, 2004
  pubmed

• 8) Samanta A, Burden AC, Jagger C:A comparison of the clinical features and vascular complications of diabetes between migrant Asians and Caucasians in Leicester, U.K. Diabetes Res Clin Pract 14:205-213, 1991

• 9) Burden AC, McNally PG, Feehally J et al:Increased incidence of end-stage renal failure secondary to diabetes mellitus in Asian ethnic groups in the United Kingdom. Diabet Med 9:641-645, 1992
  pubmed

• 10) Young BA, Katon WJ, Von Korff M et al:Racial and ethnic differences in microalbuminuria prevalence in a diabetes population:the pathways study. J Am Soc Nephrol 16:219-228, 2005

• 11) Keen H, Lee ET, Russell D et al:The appearance of retinopathy and progression to proliferative retinopathy:the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 44 (Suppl 2):S22-S30, 2001

• 12) Tesfaye S, Chaturvedi N, Eaton SE et al:EURODIAB Prospective Complications Study Group:Vascular risk factors and diabetic neuropathy. N Engl J Med 352:341-350, 2005

• 13) Sone H, Mizuno S, Yamada N:Vascular risk factors and diabetic neuropathy. N Engl J Med 352:1925-1927, 2005
  pubmed

• 14) Howard AA, Arnsten JH, Gourevitch MN:Effect of alcohol consumption on diabetes mellitus:a systematic review. Ann Intern Med 140:211-219, 2004
  pubmed

• 15) Sone H, Mizuno S, Aida R et al:Alcohol use and diabetes mellitus. Ann Intern Med 141:408-409, 2004
  pubmed

• 16) Sone H, Yamada N, Mizuno S et al:Requirement for hypertension and hyperlipidemia medication in U.S. and Japanese patients with diabetes. Am J Med 117:711-712, 2004
  pubmed

• 17) メタボリックシンドローム診断基準検討委員会:メタボリックシンドロームの定義と診断基準. 日本内科学会誌 94:794-809, 2005

• 18) Kahn R, Buse J, Ferrannini E et al:American Diabetes Association; European Association for the Study of Diabetes. The metabolic syndrome:time for a critical appraisal:joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28:2289-2304, 2005

• 19) Alberti KG, Zimmet P, Shaw J:IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet 366:1059-1062, 2005

• 20) World Health Organization:Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1:diagnosis and classification of diabetes mellitus. Genova, Switzerland:Department of non-communicable Disease Surveillance, 1999

• 21) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults:Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001

• 22) Grundy SM, Cleeman Jl, Daniels SR et al:Diagnosis and management of the metabolic syndrome:an American Heart Association National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735-2752, 2005

• 23) Sone H, Mizuno S, Fujii H et al:Japan Diabetes Complications Study. Is the diagnosis of metabolic syndrome useful for predicting cardiovascular disease in asian diabetic patients? Analysis from the Japan Diabetes Complications Study. Diabetes Care 28:1463-1471, 2005

• 24) Sone H, Tanaka S, Ishibashi S et al:Japan Diabetes Complications Study (JDCS) Group:The new worldwide definition of metabolic syndrome is not a better diagnostic predictor of cardiovascular disease in Japanese diabetic patients than the existing definitions. Additional analysis from the Japan Diabetes Complications Study. Diabetes Care 29:145-147, 2006

• 25) Chan WB, Tong PC, Chow CC et al:Triglyceride predicts cardiovascular mortality and its relationship with glycaemia and obesity in Chinese type 2 diabetic patients. Diabetes Metab Res Rev 21:183-188, 2005
  pubmed

• 26) Yamamoto A, Richie G, Nakamura H et al:ASPAC study members in Japan; Research Committee on Serum Lipid Survey 1990 Japan:Risk factors for coronary heart disease in the Japanese-comparison of the background of patients with acute coronary syndrome in the ASPAC study with data obtained from the general population. Asia-Pacific Collaboration on CHD Risk Factor Intervention study. J Atheroscler Thromb 9:191-199, 2002

• 27) Yamada N, Yoshinaga H, Sakurai N et al:Increased risk factors for coronary artery disease in Japanese subjects with hyperinsulinemia or glucose intolerance. Diabetes Care 17:107-114, 1994
  pubmed

P.51 掲載の参考文献

• 1) 弘世貴久:経口内服薬の使い方, プライマリーケアに役立つ糖尿病治療ポイント. 日本医事新報 4193:6-12, 2004

• 2) 松澤佑次, 弘世貴久, 河盛隆造ほか監修:病気がみえるvol.3 代謝内分泌疾患. 医療情報科学研究所編, メディックメディア, 東京, 2004, p. 38

• 3) 弘世貴久:グリニド系薬剤に学ぶインスリン分泌パターンの重要性. 日本臨牀 63:2237-2244, 2005
  Medical*Online

• 4) Igarashi Y, Mita T, Mizuno R et al:Characteristics of Japanese subjects who progress from normal to impaired glucose tolerance. Longitudinal study excluding changes in body weight. Endocr J 52:683-689, 2005
  pubmed

• 5) 弘世貴久:速効型インスリン分泌促進薬による食後高血糖管理-α-Glの併用は?, 食後高血糖の病態・診断・治療. Current Therapy 特別号:77-81, 2006

• 6) Uchino H, Niwa M, Shimizu T et al:Impairment of early insulin response after glucose load rather than insulin resistance, is obese type 2 diabetes:assessment using nateglinide, a new insulin secretagogue. Endocr J 47:639-641, 2000
  pubmed

• 7) Kurebayashi S, Watada H, Tanaka Y et al:Efficacy and adverse effects of nateglinide in early type 2 diabetes. comparison with voglibose in a cross-over study. Endocr J 53:213-217, 2006

P.56 掲載の参考文献

• 1) 田嶼尚子:糖尿病ハイリスク群の効率的なスクリーニング:Prog Med 25:15-21, 2005
  Medical*Online

• 2) The DECODA Study (Diabetes Epidemiology:Collaborative Analysis of Diagnostic Criteria in Asia):Cardiovascular risk profile assessment in glucose-intolerant Asian individuals:an evaluation of the World Health Organization two-step strategy. Diabetic Med 19:549-557, 2002

• 3) Nakagami T, Quio Q, Tuomilehto J et al:The fasting plasma glucose cut-point predicting a diabetic 2-h OGTT glucose level depends on the phenotype. Diabetes Res Clin Pract 55:35-43, 2002

• 4) 富永真琴, 中神朋子:実地医療のなかで, どのように食後高血糖をみつけるか? -舟形町 study を踏まえて. Current Therapy 特別号:60-64, 2006

• 5) Genuth S, Alberti KG, Bennett P et al:Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:3160-3167, 2003

• 6) 伊藤千賀子:糖尿病の病態と検査. 糖尿病の予防と管理-疫学研究よるアプローチ, 診断と治療社, 東京, 2002, pp.1O-15

• 7) Ko GT, Chan JC, Tsang LW et al:Combined used of fasting plasma glucose and HbA1c predicts the progression to diabetes in Chinese subjects. Diabetes Care 23:1770-1773, 2000
  pubmed

• 8) Akutsu T, Mori Y, Itoh Y et al:Potential role of 1.5-Anhydro-D-glucitol in screening for impaired glucose tolerance. Diabetes 54 (Suppl 1):A96, 2005

• 9) Nelson KM, Boyko EJ:Third National Health and Nutrition Examination Survey. Predicting impaired glucose tolerance using common clinical information:data from the Third National Health and Nutrition Examination Survey. Diabetes Care 26:2058-2062, 2003
  pubmed

• 10) Spijkerman AM, Adriaanse MC, Dekker JM et al:Diabetic patients detected by population based stepwise screening already have a diabetic cardiovascular risk profile. Diabetes Care 25:1784-1789, 2002
  pubmed

• 11) Lindstrom J, Tuomilehto J:The diabetic risk score:a practical tool to predict type 2 diabetes risk. Diabetes Care 26:725-731, 2003
  pubmed

• 12) Glumer C, Jorgensen T, Borch-Johnsen K:Targeted screening for undiagnosed diabetes reduces the number of diagnostic test. Inter99 (8) . Diabet Med 21:874-880, 2004
  pubmed

P.61 掲載の参考文献

• 1) 清野弘明, 武井泉, 笠谷知宏:1型および2型糖尿病における血糖自己測定の適応, とくにインスリン投与へのフィードバックにおける血糖自己測定の活用と指導. 患者指導のためのSMBGのすべて (改訂第2版), 富永真琴編, 日本医学出版, 東京, 2005, pp.21-24

• 2) 渥美義仁, 門脇孝, SCCTグループ:血糖自己測定と SCCT. 分子糖尿病学の進歩, 門脇孝, 春日雅人, 菅野進ほか編, 金原出版, 東京, 1998, pp.147-150

• 3) 内潟安子:SMBGによるインスリン治療へのフィードバック. プラクティス別冊, SMBG血糖自己測定, 医歯薬出版, 東京, 2001, pp.69-75

P.69 掲載の参考文献

• 1) Araki S, Haneda M, Sugimoto T et al:Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes 54:2983-2987, 2005
  pubmed

• 2) 日本糖尿病学会編:糖尿病治療ガイド, 2006〜2007, 文光堂, 東京

• 3) 日本糖尿病学会編:科学的根拠に基づく糖尿病診療ガイドライン. 南江堂, 東京, 2004

• 4) 日本高血圧学会:高血圧治療ガイドライン, 2004

P.75 掲載の参考文献

• 1) Knowler WC, Barrett-Connor E, Fowler SE et al:Diabetes Prevention Program Research Group:Reduction in the incidence of type 2 diabetes with lifestyle intervention or metoformin. N Engl J Med 346:393-403, 2002

• 2) Tuomilehto J, Lindstrom J, Eriksson J et al:Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose. N Engl J Med 344:1343-1350, 2001
  pubmed

• 3) 日本糖尿病学会編:糖尿病食事療法のための食品交換表, 第6版. 文光堂, 東京, 2002

• 4) Jarvi AE, Karlstom BE, Granfeldt YE et al:Improved glycemic control and lipid profile and normalized fibrinolytic activity on a low-glycemic index diet in type 2 diabetic patients. Diabetes Care 22:10-18, 1999
  pubmed

• 5) 日本糖尿病学会編:糖尿病腎症の食品交換表. 文光堂, 東京, 1998

P.80 掲載の参考文献

• 1) 藤沼宏彰:糖尿病と運動. 医歯薬出版, 東京, 2005

• 2) Tominaga M, Eguchi H, Manaka H et al:Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose:the Funagata Diabetes Study. Diabetes Care 22:920-924, 1999

• 3) DECODE study group:Glucose tolerance and cardiovascular mortality:Comparsion of fasting and 2-hour diagnostic criteria. Arch Intern Med 161:397-405, 2001

• 4) Chiasson JL, Josse RG, Gomis R et al:Acarbose treatment and the risk of cardiovascular disease and hypertention in patients with impaired glucose tolerance. JAMA 290:486-494, 2003

• 5) Fagard RH:Prescription and results of physical activity. J Cardiovasc Pharmacol 25 (Supple 1):S20-S27, 1995

• 6) Huttunen JKE:Effect of a moderate physical exercise on serum lipoproteins:a controlled clinical trial with special reference to serum high-density lipoproteins. Circulation 60:1220-1229, 1979

• 7) 清野弘明, 藤沼宏彰:合併症による運動療法の修飾. 糖尿病 47:632-634, 2004

PART 3 生活習慣病の初期症状としての早期糖尿病をみる

P.89 掲載の参考文献

• 1) 森豊:インスリン分泌異常, 食後高血糖. Mebio別冊, 食後高血糖/IGT と大血管障害, 山田信博編, メジカルビュー社, 東京, 2003, pp.26-37

• 2) Tominaga M, Eguchi H, Manaka H et al:Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. Diabetes Care 22:920-924, 1999

• 3) Hanefeld M, Koehler C, Henkel E et al:Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima-media thickness:the RIAD study. Diabet Med 17:835-840, 2000
  pubmed

• 4) DECODE Study Group:Glucose tolerance and mortality-Comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354:617, 1999

• 5) Mori Y, Hoshino K, Yokota K et al:Increased visceral fat and impaired glucose tolerance predict the increased risk of metabolic syndrome in Japanese middle-aged men. Exp Clin Endocrinol Diabetes 113:334-339, 2005
  pubmed

• 6) Mori Y, Hoshino K, Yokota K et al:Japanese IGT subjects with high insulin response are far more frequently associated with the metabolic syndrome than those with low insulin response. Endocrine 29:351-355, 2006
  pubmed

• 7) Akutsu T, Mori Y:Differences in the risk for atherosclerosis in subjects with impaired glucose tolerance with and without visceral fat accumulation:A study in Japanese middle-aged men. Jikeika:Med J 53:31-36, 2006

• 8) メタボリックシンドローム診断基準検討委員会:メタボリックシンドロームの定義と診断基準. 日本内科会誌 94:188-203, 2005

• 9) 竹内宏, 斉藤重幸, 高木覚ほか:日本人におけるMetabolic Syndrome とインスリン抵抗性の検討-端野・壮瞥研究-. 糖尿病 46:739-744, 2003

• 10) Mori Y, Hoshino K, Yokota K et al:Differences in the pathology of the Metabolic syndrome with or without visceral fat accumulation:a study in pre-diabetic Japanese middle-aged men. Endocrine 29:149-153, 2006

• 11) Mori Y, Hoshino K, Yokota K et al:Role of hypoadiponectinemia in the metabolic syndrome and its association with post-glucose challenge hyper-free fatty acidemia:A study in prediabetic Japanese men. Endocrine 29:357-361, 2006

• 12) Tuomilehto J, Lindrom J, Eriksson JG et al:Prevention of type 2 diabetes mellitus by changes in life style among subjects with impaired glucose tolerance. N Eng J Med 344:1343-1350, 2001

• 13) Knowler WC, Barrett-Connor E, Fowler SE et al:Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002

• 14) Pan XR, Li GW, Hu YH et al:Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20:537-544, 1997

• 15) McMurray JJ, Califf R, Holman R et al:Cardiologists should care about glucose:most people with CV disease or risk factors have diabetes or significant glycaemic abnormalities. Results of screening over 39,000 subjects for NAVIGATOR. ESC Congress, 2004

• 16) Chiasson JL Josse RG, Gomis R et al:Acarbose for prevention of type 2 diabetes mellitus:the STOP-NIDDM randomized trial. Lancet 359:2072-2077, 2002
  pubmed

• 17) Julius S, Kjeldsen SE, Weber M et al:Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on varsartan or amlodipine:the VALUE randomized trial. Lancet 363:2022-2031, 2004
  pubmed

• 18) Tenenbaum A, Motro M, Fisman EZ et al:Peroxisome proliferators-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 109:2197-2202, 2004

• 19) Tenenbaum A, Motro M, Fisman EZ et al:Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 165:1154-1160, 2005
  pubmed

P.93 掲載の参考文献

• 1) Grundy SM, Benjamin IJ, Burke GL et al:Diabetes and cardiovascular disease:a statement for healthcare professionals from the American Heart Association. Circulation 100:1134-1146, 1999
  pubmed

• 2) Rubler S, Dlugash J, Yuceoglu YZ et al:New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30:595-602, 1972
  pubmed

• 3) Mizushige K, Yao L Noma T et al:Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation 101:899-907, 2000
  pubmed

• 4) Celentano A, Vaccaro O, Tammaro P et al:Early abnormalities of cardiac function in non-insulin-dependent diabetes mellitus and impaired glucose tolerance. Am J Cardiol 76:1173-1176, 1995
  pubmed

• 5) Petrova R, Yamamoto Y, Muraki K et al:Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes. J Mol Cell Cardiol 34:1425-1431, 2002
  pubmed

• 6) Frustaci A, Kajstura J, Chimenti C et al:Myocardial cell death in human diabetes. Circ Res 87:1123-1132, 2000
  pubmed

• 7) Wakasaki H, Koya D, Schoen FJ et al:Targeted overexpression of protein kinase C β2 isoform in myocardium causes cardiomyopathy. Proc Natl Acad Sci USA 94:9320-9325, 1997

• 8) Shindler DM, Kostis JB, Yusuf S et al:Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 77:1017-1020, 1996
  pubmed

• 9) Iribarren C, Karter AJ, Go AS et al:Glycemic control and heart failure among adult patients with diabetes. Circulation 103:2668-2673, 2001
  pubmed

• 10) Stratton IM, Adler Al, Neil HA et al:Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35):prospective observational study. BMJ 321:405-412, 2000

P.97 掲載の参考文献

• 1) Kataoka Y, Yasuda S, Morii I et al:Quantitative coronary angiographic studies of patients with angina pectoris and impaired glucose tolerance. Diabetes Care 28:2217-2222, 2005
  pubmed

• 2) Norhammar A, Tenerz A, Nilsson G et al:Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus:a prospective study. Lancet 359:2140-2144, 2002
  pubmed

• 3) Luscher TF, Creager MA, Beckman JA et al:Diabetes and vascular disease:pathophysiology, clinical consequences, and medical therapy:Part II. Circulation 108:1655-1661, 2003
  pubmed

• 4) Esposito K, Nappo F, Marfella R et al:Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans:role of oxidative stress. Circulation 106:2067-2072, 2002
  pubmed

P.101 掲載の参考文献

• 1) Alberti KG, Zimmet PZ:Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1:diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539-553, 1998
  pubmed

• 2) 清原裕, 大久保賢, 谷崎弓裕:血管障害の危険因子としての境界型. 第35回「糖尿病学の進歩」シンポジウム:効率的な一次予防のあり方, 2001

• 3) The DECODE Study Group:Glucose tolerance and cardiovascular mortality:comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161:397-405, 2001

• 4) Giugliano D, Ceriello A, Paolisso G:Oxidative stress and diabetic vascular complications. Diabetes Care 19:257-267, 1996

• 5) Ruef J, Liu SQ, Bode C et al:Involvement of aldose reductase in vascular smooth muscle cell growth and lesion formation after arterial injury. Arterioscler Thromb Vasc Biol:20:1745-1752, 2000
  pubmed

• 6) Inoguchi T, Battan R, Handler E et al:Preferential elevation of protein kinase C isoform β II and diacylglycerol levels in the aorta and heart of diabetic rats:differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci USA 89:11059-11063, 1992

• 7) Kirstein M, Brett J, Radoff S et al:Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor:role in vascular disease of diabetes and aging. Proc Natl Acad Sci USA 87:9010-9014, 1990
  pubmed

• 8) Vinters HV, Berliner JA, Beck DW et al:Insulin stimulates DNA synthesis in cerebral microvessel endothelium and smooth muscle. Diabetes 34:964-969, 1985
  pubmed

• 9) Touyz RM:Molecular and cellular mechanisms regulating vascular function and structure-implications in the pathogenesis of hypertension. Can J Cardiol 16:1137-1146, 2000
  pubmed

• 10) Verges B:New insight into the pathophysiology of lipid abnormalities in type 2 diabetes. Diabetes Metab 31:429-439, 2005
  pubmed

• 11) Carr ME:Diabetes mellitus:a hypercoagulable state. J Diabetes Complications 15:44-54, 2001
  pubmed

• 12) Wakisaka M, Nagamachi S, Inoue K et al:Reduced regional cerebral blood flow in aged noninsulin-dependent diabetic patients with no history of cerebrovascular disease:evaluation by N-isopropyl-123l-p-iodoamphetamine with single-photon emission computed tomography. J Diabet Complications 4:170-174, 1990

P.106 掲載の参考文献

• 1) 島袋充生:循環器医が治療する糖尿病と大血管障害. 代田浩之, 野出孝一編, メジカルビュー社, 東京, 2004, pp.298-290

• 2) 島袋充生:食後高血糖と軽症糖尿病:その意義と治療の実際. Medical Practice 22:1779-1783, 2005
  Medical*Online

• 3) THE DECODE STUDY GROUP, European Diabetes Epidemiology Group:Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 26:688-696, 2003

• 4) Tominaga M, Eguchi H, Manaka H et al:Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22:920-924, 1999

• 5) Hanefeld M, Fischer S, Julius U et al:Risk factors for myocardial infarction and death in newly detected NIDDM:the Diabetes Intervention Study, 11-year follow-up. Diabetologia 39:1577-1583, 1996
  pubmed

• 6) De Vriese AS, Verbeuren TJ, Van de Voorde J et al:Vanhoutte PM. Endothelial dysfunction in diabetes. Br J Pharmacol 130:963-974, 2000
  pubmed

• 7) Guzik TJ, Mussa S, Gastaldi D et al:Mechanisms of increased vascular superoxide production in human diabetes mellitus:role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 105:1656-1662, 2002
  pubmed

• 8) Carr ME:Diabetes mellitus:A hypercoagulable state. J Diabetes Complications 15:44-54, 2001
  pubmed

• 9) Shimabukuro M, Higa N, Takasu N et al:A single dose of nateglinide improves post-challenge glucose metabolism and endothelial dysfunction in type 2 diabetic patients. Diabet Med 21:983-986, 2004
  pubmed

• 10) Shimabukuro M, Higa N, Chinen l et al:Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients:a randomized cross-over study. J Clin Endocrinol Metab 91:837-842, 2006

P.111 掲載の参考文献

• 1) Sakamoto T, Ogawa H, Kawano H et al:Rapid change of platelet aggregability in acute hyperglycemia. Detection by a novel laser-light scattering method. Thromb Haemost 83:475-479, 2000
  pubmed

• 2) Sakamoto T, Yasue H, Ogawa H et al:Association of patency of the infarct-related coronary artery with plasma levels of plasminogen activator inhibitor activity in acute myocardial infarction. Am J Cardiol 70:271-276, 1992
  pubmed

• 3) Calles-Escandon J, Mirza SA, Sobel BE et al:Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes 47:290-293, 1998
  pubmed

P.118 掲載の参考文献

• 1) Ludwig J, Viggiano TR, McGill DB et al:Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55:434-438, 1980

• 2) Neuschwander-Tetri BA, Caldwell SH:Nonalcoholic steatohepatitis:Summary of an AASLD Single Topic Conference. Heppatology 37:1202-1219, 2003
  pubmed

• 3) American Gastroenterological Association:medical position statement:nonalcoholic fatty liver d isease. Gastroenterology 123:1702-1725, 2002

• 4) Matteoni CA, Younossi ZM, Gramlich T et al:Nonalcoholic fatty liver disease:A spectrum of clinical and pathological severity. Gastroenterology 116:1413-1419, 1999
  pubmed

• 5) Brunt EM:Nonalcoholic steatohepatitis. Semin Liver Dis 24:3-21, 2004
  pubmed

• 6) Kaneda H, Hashimoto E, Yatsuji S et al:Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol:in press

• 7) Bedogni G, Miglioli L, Masutti F et al:Prevalence of and risk factors for nonalcoholic fatty liver disease:the Dionysos nutrition and liver study. Hepatology 42:44-53, 2005
  pubmed

• 8) Kojima S, Watanabe N, Nomata M et al:Increase in the prevalence of fatty liver in Japan over the past 12 years:analysis of clinical background. J Gastroenterol 38:954-961, 2003

• 9) Hashimoto E, Yatsuji S, Kaneda H et al:The characteristics and natural history of Japanese patient with nonalcoholic fatty liver disease. Hepatol Res 33:72-76, 2005
  pubmed

• 10) Shimada M, Hashimoto E, Taniai M et al:Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 37:154-160, 2002
  pubmed

P.125 掲載の参考文献

• 1) Kawamori R, Yamasaki Y, Matsushima H et al:Prevalence of carotid atherosclerosis in diabetic patients-Ultrasound, high resolution B-mode imaging on the carotid arteries-. Diabetes Care 15:1290-1294, 1992
  pubmed

• 2) Mitsuhashi N, Onuma T, Kubo S et al:Coronary artery disease and carotid artery intima-media thickness in Japanese type 2 diabetic patients. Diabetes Care 25:1308-1312, 2002
  pubmed

• 3) Yamasaki Y, Kawamori R, Matsushima H et al:Asymptomatic hyperglycemia is associated with increased intimal plus medial thickness of carotid artery. Diabetologia 38:585-591, 1995
  pubmed

• 4) Kawamori R:Asymptomatic hyperglycaemia and early atherosclerotic changes. Diab Res Clin Pract 40 (Supple 1):S35-S42, 1998

• 5) Shao J, Iwashita N, lkeda F et al:Beneficial effects of candesartan, an angiotensin II type I receptor blocker, on β-cell function and morphology in db/db mice. Biochem Biophys Res Commun 344:1224-1233, 2006

P.130 掲載の参考文献

• 1) Owens DR, Zinman B, Bolli GB:Insulins today and beyond. Lancet 358:739-746, 2001
  pubmed

• 2) Kruszynska YT, Home PD, Hanning I et al:Basal and 24-h C-peptide and insulin secretion rate in normal man. Diabetologia 30:16-21, 1987

• 3) Polonsky KS, Given BD, Van Cauter E:Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 81:442-448, 1988
  pubmed

• 4) Simon C, Follenius M, Branderberger G:Postprandial oscillation of plasma glucose, insulin and C-peptide in man. Diabetogia 30:769-773, 1987

• 5) Shapiro ET, Tillil H, Polonsky KS et al:Oscillations in insulin secretion during constant glucose infusion in normal man:relationship to changes in plasma glucose. J Clin Endcrinol Metab 67:307-314, 1988

• 6) Simon C, Branderberger G, Follenius M:Ultradian oscillations of plasma glucose, insulin and C-peptide in man during continuous enteral nutrition. Clin Endcrinol Metab 64:669-674, 1987

• 7) Van Cauter E, Desir D, Decoster C et al:Nocturnal decrease in glucose tolerance during constant glucose infusion. J Clin Endocrinol Metab 69:604-611, 1989
  pubmed

• 8) Quast U, Stephan D, Bieger S et al:The impact of ATP-sensitive K+ channel subtype sensitivity of insulin secretagogues for the coronary vasculature and the myocardium. Diabetes 53 (Suppl 3):S156-S164, 2004

• 9) Gribble FM, Manley SE, Levy JC:Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (a-4166). Diabetes Care 24:1221-1225, 2001
  pubmed

• 10) Weaver ML Orwig BA, Rodriguez LC et al:Pharmacokinetics and metabolism of nateglinide in humans. Drug Metab Dispos 29:415-421, 2001
  pubmed

• 11) Kalbag JB, Walter YH, Nedelman JR et al:Mealtime glucose regulation with nateglinide in healthy volunteers:comparison with rapaglinide and placebo. Diabetes Care 24:73-77, 2001

• 12) Levien TL Baker DE, Campbell RK et al:Nateglinide therapy for type 2 diabetes mellitus. Am Pharmacother 35:1426-1434, 2001

• 13) Hu S, Wang S, Fanelli B et al:Pancreatic β-cell K (ATP) channel activity and membrane-binding studies with nateglinide:a comparison with sulfonyiureas and repaglinide. J Pharmacol Exp Ther 293:444-452, 2000

• 14) Saloranta C, Hershon K, Ball M et al:Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia. J Clin Endocrinol Metab 87:4171-4176, 2002
  pubmed

P.135 掲載の参考文献

• 1) Rossetti L Hawkins M, Chen W et al:In vivo glucosamine infusion induces insulin resistance in normoglycemic but not in hyperglycemic conscious rats. J Clin vest 96:132-140, 1995
  pubmed

• 2) Yki-Jarvinen, Daniels MC, Virkamaki A et al:Increased glutamine:fructose-6-phosphatase amido-transferase activity in skeletal muscle of patients with NIDDM. Diabetes 45:302-307, 1996

• 3) Vosseller K, Wells L Lane MD et al:Elevated nucleocytoplasmic glycosylation by-GlcNac results in insulin resistance associated with defects defects in Akt activation in 3T3-L1 adipopcytes. Proc Natl Acad Sci USA 99:5313-5318, 2002
  pubmed

• 4) Nakatani Y, Kaneto H, Kawamori D et al:Modulation of the JNK pathway in liver affects insulin resistance status. J Biol Chem 279:45803-45809, 2004
  pubmed

• 5) Kaneto H, Nakatani Y, Miyatsuka T et al:Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide. Nat Med 10:1128-1132, 2004
  pubmed

• 6) Ozcan U, Cao Q, Yilmaz E et al:Endoplasmic reticulum stress links obesity, insulin resistance and diabetes. Science 306:457-461, 2004
  pubmed

• 7) Nakatani Y, Kaneto H, Matsuhisa M et al:Increased stress protein ORP150 autoantibody production in type 1 diabetic patients. Diabet Med 23:216-219, 2005

• 8) Nakatani Y, Kaneto H, Matsuhisa M et al:Involvement of endoplasmic reticulum stress in insulin resistance and diabetes. J Biol Chem 280:847-851, 2005
  pubmed

• 9) Hazama Y, Matsuhisa M, Ohtoshi K et al:Beneficial effects of nateglinide on insulin resistance in type 2 diabetes. Diabetes Res Clin Pract 71:251-255, 2006
  pubmed

• 10) Delgado H, Lehmann T, Bobbioni-Harsch E et al:Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetic patients. Diabetes Metab 28:195-200, 2002
  pubmed

• 11) Lin Y, Berg AH, lyengar P et al:The hyperglycemia-induced inflammatory response in adipocytes. J Biol Chem 280:4617-4626, 2005

• 12) Assloni R, Ros RD, Quagliaro L et al:Effect of S2104 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients. Diabetologia 48:1919-1924, 2005

• 13) Ohtoshi K, Yamasaki Y, Gorogawa S et al:Association of-786T-C mutation of endotherial nitric oxide synthase gene with insulin resistance. Diabetologia 45:1594-1601, 2002

P.140 掲載の参考文献

• 1) Ai M, Tanaka A, Ogita K et al:Relationship between insulin concentration and plasma remnant lipoprotein response to an oral fat load in patients with type 2 diabetes. J Am Coll Cardiol 38:1628-1632, 2001

• 2) Kim HS, Abbasi F, Lamendola C et al:Effect of insulin resistance on postprandial elevations of remnant lipoprotein concentrations in postmenopausal women. Am J Clin Nutr 74:592-595, 2001
  pubmed

• 3) メタボリックシンドローム診断基準検討委員会. メタボリックシンドロームの定義と診断基準. 日本内科学会雑誌 94:188-202, 2005

• 4) Nakajima K, Okazaki M, Tanaka A et al:Separation and determination of remnant-like particles in human serum using monoclonal antibodies to apo B100 and apo A-I. J Clinical Ligand Assay 19:177-183, 1996

• 5) Tanaka A:Posrprandial hyperlipidemia and atherosclerosis. J Atheroscler Tromb 11:322-329, 2004

PART 4 早期糖尿病からはじめる糖尿病治療の新たなアプローチをみる

P.145 掲載の参考文献

• 1) Tominaga M, Eguchi H, manaka H et al:Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose:The Funagata Diabetes Study. Diabetes Care 22:920-924, 1999

• 2) UK Prospective Diabetes Study (UKPDS) Group:Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
  pubmed

• 3) UK Prospective Diabetes Study (UKPDS) Group:Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998

• 4) Dormandy JA Charbonnel B, Eckland DA et al:On behalf of the PROactive investigators:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):a randomized controlled trial. Lancet 366:1279-1289, 2005

• 5) Chiasson JL, Josse RG, Gomis R et al:for The STOP-NIDDM Trial Research Group:Acarbose treatment and the risk of condiovascular disease and hypertension in patients with impaired glucose tolerance:the STOP-NIDDM trial. JAMA 290:486-494, 2003

• 6) Hanefeld M, Cagatay M, Pettowisch T et al:Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients:meta-analysis of seven long-term studies. Eur Heart J 25:10-16, 2004

P.149 掲載の参考文献

• 1) Fujita T, Seto Y, Kondo N et al:Studies on the N-[(trans-4-isopropylcyclohexyl)-carbonyl]D-phenylalanine (A-4166) receptor in HIT T-15cells. Biochem Pharmacol 52:407-411, 1996

• 2) Tripathy D, Carlsson M, Almgren P et al:Insulin secretion and insulin sensitivity in relation to glucose tolerance:lessons from the Botnia Study, Diabetes 49:975-980, 2000
  pubmed

• 3) Fukushima M, Suzuki H, Seino Y:Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract 66 (Supple 1):S37-S43, 2004

• 4) Mitsui R, Fukushima M, Nishi Y et al:Factors responsible for deteriorating glucose tolerance in newly diagnosed type 2 diabetes in Japanese men. Metabolism 55:53-58, 2006
  pubmed

• 5) Suzuki H, Fukushima M, Usami M et al:Factors responsible for development from normal glucose tolerance to isolated postchallenge hyperglycemia. Diabetes Care 26:1211-1215, 2003
  pubmed

• 6) Kuroe A, Fukushima M, Usami M et al:Impaired β-cell function and insulin sensitivity in Japanese subjects with normal glucose tolerance. Diabetes Res Clin Pract 59:71-77, 2003

• 7) Hollander PA, Schwartz SL Gatlin MR et al:Importance of early insulin secretion:comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 24:983-988, 2001
  pubmed

P.154 掲載の参考文献

• 1) Uchino H, Niwa M, Shimizu T et al:Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabedtes; assessment using nateglinide, a new insulin secretagogue. Endocr J 47:639-941, 2000
  pubmed

• 2) Ai M, Tanaka A, Ogita K et al:Relationship between plasma insulin concentration and plasma remnant lipoprotein response to an oral fat load in patients with type 2 diabetes. J Am Coll Cardiol 38:1628-1632, 2001

• 3) Zilversmit DB:Atherogenesis:a postprandial phenomenon. Circulation 60:473-485, 1979
  pubmed

• 4) Tanaka A, Tomie N, Nakano T et al:Measurement of postprandial remnant-like particles (RLPs) following a fat-loading test. Clin Chem Acta 275:43-52, 1998

• 5) Takase H, Shoji K, Hase T et al:Effect of diacylglycerol on postprandial lipid metabolism in non-diabetic subjects with and without insulin resistance. Atherosclerosis 180:197-204, 2005
  pubmed

• 6) Ai M, Tanaka A, Ogita K et al:Favorable effects of early insulin secretion by nateglinide on postprandial hyperlipidemia in patients with type 2 diabetes. Diabetes Care 29:1180, 2006
  pubmed

• 7) Mori Y, Kuriyama G, Tajima N:Effects of nateglinide on the elevation of postprandial remnant-like particle triglyceride levels in Japanese patients with type 2 diabetes assessment by meal tolerance test. Endocrine 25:203-206, 2004
  pubmed

P.159 掲載の参考文献

• 1) Angulo P:Nonalcoholic fatty liver disease. N Engl J Med 346:1221-1231, 2002
  pubmed

• 2) Promrat K, Lutchman G, Uwaifo Gl et al:A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39:188-196, 2004

• 3) Marchesini G, Brizi M, Bianchi G et al:Metformin in non-alcoholic steatohepatitis. Lancet 358:893-894, 2002

• 4) Morita Y, Ueno T, Sasaki N et al:. Nateglinide is useful for nonalcoholic steatohepatitis (NASH) patients with type 2 diabetes. Hepatogastroenterology 52:1338-1343, 2005
  pubmed

P.164 掲載の参考文献

• 1) Leventhal H, Meyer D, Nerenz D:The common sense representation of illness danger. In:Rachman S ed. Medical Psychology, Pergamon Press, New York, 1980, pp.7-30

• 2) Becker MH (Ed):The health belief model and personal health behavior. Health Education Monographs 2:324-508, 1974

• 3) Bandura A:Self efficacy:Toward a unifying theory of behavior change. Psychological review 84:191-215, 1977

• 4) Smith DE, Heckemeyer CM, Kratt PP et al:Motivational interviewing to improve adherence to a behavioral weight-control program for older obese woman with NIDDM:a pilot study. Diabetes Care 20:52-54, 1997
  pubmed

• 5) Prochaska JO, DiClemmente CC, Norcross JC:In search of how people change:Applications to addictive behaviors. Am Psychol 47:1102-1114, 1992

• 6) 石井均:インスリン治療患者における心理面の問題. 糖尿病の薬物治療. 難波光義編, 文光堂, 東京, 2006

P.170 掲載の参考文献

• 1) Hogue JK, Kinahan JJ, Delcher HK:A hospital-based home health diabetes education model. Home Healthc Nurse 14:372-377, 1996
  pubmed

• 2) 佐々木宏美, 澤田由紀子, 芝山信子:クリティカルパスを用いた境界型の糖尿病教育入院の効果-身体状況と食行動の変化-. プラクティス 20:612-613, 2003
  Medical*Online

• 3) Crane M, Werber B:Critical pathway approach to diabetic pedal infections in a multidisciplinary setting. J Foot Ankle Surg 38:30-33, 1999

• 4) Ilag LL, Kronick S, Ernst RD et al:Impact of a critical pathway on inpatient management of diabetic ketoacidosis. Diabetes Res Clin Pract 62:23-32, 2003
  pubmed

• 5) Courtney L, Gordon M, Romer L:A clinical path for adult diabetes. Diabetes Educ 23:664-671, 1997
  pubmed

• 6) Diabetes pathway slashes length of stay by 26%. Hosp Case Manag 7:8, 13, 1999
  pubmed

• 7) Pathway keeps LOS low for young diabtes patients. Hosp Case Manag 13:150, 159-160, 2005